Express News | AxoGen Inc : Raymond James Initiates Coverage With Outperform Rating; Target Price $13

BreakingsJul 1 19:15

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an

GlobeNewswireJul 1 19:00

Raymond James Initiates AxoGen(AXGN.US) With Buy Rating, Announces Target Price $13

Raymond James analyst Jayson Bedford initiates coverage on $AxoGen(AXGN.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 64.2% and

Futu NewsJul 1 18:31 · Ratings

Axogen Initiated at Outperform by Raymond James

Axogen Initiated at Outperform by Raymond James

Dow JonesJul 1 18:18

Raymond James Initiates Coverage On Axogen With Outperform Rating, Announces Price Target of $13

Raymond James analyst Jayson Bedford initiates coverage on Axogen (NASDAQ:AXGN) with a Outperform rating and announces Price Target of $13.

BenzingaJul 1 18:09

AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection

Yahoo FinanceJun 26 00:52